Zydus Lifesciences shares fly 7% as USFDA okays cancer drug Dasatinib

Quick Summary:

Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in the chronic phase.

Notably, Dasatinib tablets generated annual sales of $1,807.7 million in the United States, according to IQVIA data from January 2025.

At 11:30 AM, Zydus Life shares were trading 1.93 per cent higher at Rs 904.65 per share.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: BusinessFinance

Markets: IndiaBrazilJapanSouth AfricaUnited States

Topics: Zydus Life share levels Zydus Life stock price today Zydus Life stocks Cancer drug Buzzing Stock NSE Zydus Life Zydus Lifesciences Zydus Life stock levels Zydus Life USFDA Zydus Life Stock Price Zydus Life share price Zydus Life Shares Zydus Life

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-03-06 @ 11:36:52 (7 hours ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 465 words

Reading Time: 3 minutes read

Sentences: 21 lines

Sentence Length: 23 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 26690883

View Article Analysis

About Business Standard

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 269 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 3 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions